Why Heart Failure Protocols Matter: Global Evidence That GDMT Underuse Is a Worldwide Problem (2025)
Why Heart Failure Protocols Matter: Global Evidence That GDMT Underuse Is a Worldwide Problem (2025)
Three major 2025 studies show clearly that underuse of GDMT is a global problem, spanning low-resource settings, primary care systems, and advanced European centers.
National protocols are the proven first step to closing this implementation gap.
Keynotes:
1) Implementation of Guideline-Directed Medical Therapy in HFrEF
Journal: BMC Cardiovascular Disorders
Date: October 2025
Setting: Hospital-based cohort in Ethiopia
Link: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-025-05187-5
Summary:
• Only 1.3% of patients reached full target GDMT doses (RASI, β-blocker, MRA).
• 0% received ARNI or SGLT2i due to cost and limited availability.
• Dose escalation was extremely rare even after treatment initiation.
• Barriers were system-level: lack of structured protocols, weak follow-up, and resource limitations.
• Conclusion: Improving GDMT requires national protocols, not individual physician effort.
2) Barriers and Facilitators to GDMT Intensification
Publisher: Springer – Journal of General Internal Medicine
Date: 2025
Setting: Multi-site U.S. primary care and community health centers
Link: https://link.springer.com/article/10.1007/s11606-025-09515-5
Key Findings:
1. Therapeutic inertia was the main barrier—hesitation to escalate therapy even when indicated.
2. Time pressure and complex comorbidities made titration difficult.
3. Limited access to cardiologists created uncertainty in decision-making.
4. Conclusion: Clear national pathways reduce inertia, improve consistency, and accelerate GDMT adoption.
3) Implementation of Recommended HF Therapy in Europe
Journal: ESC Heart Failure
Date: April 2025
Link: https://pubmed.ncbi.nlm.nih.gov/39632549/
Key Findings:
1. Fewer than 50% of patients received all recommended GDMT drug classes.
2. Achieving target doses was even less common, demonstrating global under-titration.
3. Centers using structured pathways and registries had significantly better implementation.
4. The study confirms that guideline awareness ≠ real-world practice.
5. Conclusion: Even Europe struggles—proving the challenge is global, not local.
Why This Matters
Without Protocols:
• Care varies by physician → inconsistent practice
• No unified monitoring or follow-up
• Dose escalation becomes rare → patients remain under-treated
With National Protocols:
• Clear titration steps reduce therapeutic inertia
• Unified referral pathways improve coordination across ED, cardiology, and primary care
• Hospitals follow one standardized HF pathway, improving quality and reducing variation
This is why the world’s leading systems — Europe, Canada, the U.S., Japan — all rely on national HF pathways.
Final Message to Physicians
Global data are clear: even top healthcare systems struggle with GDMT, and improvement only occurs after adopting unified national HF pathways.
Launching national protocols is not cosmetic — it is the proven foundation for better outcomes.
Jordan is now taking the same successful step that advanced systems took before achieving measurable progress.
References (Direct Links)
1. BMC Cardiovascular Disorders (2025) – Implementation of GDMT
https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-025-05187-5
2. Springer (2025) – Barriers and Facilitators to GDMT Intensification
https://link.springer.com/article/10.1007/s11606-025-09515-5
3. ESC Heart Failure (2025) – GDMT Implementation in Europe
